Thursday, November 5, 2026
26.2 C
Bengaluru

Anup Soans

Reach out to Anup Soans: anupsoans@medicinman.net.

Indian Pharma 2026: The Growth Engine Is Changing

The Indian Pharmaceutical Market isn't just growing. Its centre of gravity is shifting. Valued at ₹2,61,790 crore, with 10.9% annual...

Anand Shetty Appointed CEO – Emerging Markets at Cadila Pharmaceuticals

Cadila Pharmaceuticals has appointed Anand Shetty as Chief Executive Officer – Emerging Markets, with responsibility for its branded formulations...

The paradox of the “Pharmacy of the World.” 💊

India has world-scale formulation capability, yet the chemistry beneath that success remains deeply concentrated in external supply chains. Official...

The Innovator’s Gene and the Generic’s Promise

A medicine must first be discovered. It must then be manufactured reliably and reach the patients who need it. India’s...

Private Equity in Indian Healthcare: Who Is Investing Beyond the Metros?

Private capital is transforming India's healthcare landscape. But is its growth reaching the people who need better healthcare access...

Anuj Pasrija Elevated to Country Lead, J&J MedTech India and Vice President – Surgery

Anuj Pasrija has been elevated to Country Lead, Johnson & Johnson MedTech India, and Vice President – Surgery, taking...
spot_imgspot_img

China’s Biopharma Strategy: A Warning and Opportunity for India

China is playing a long game in biopharma. And India needs to pay attention. China has set an ambitious target:...

Chirag Mehta has been appointed as Executive Director at ERIS Lifesciences.

With over two decades of experience across finance, strategy, mergers and acquisitions, and the pharmaceutical industry, Chirag brings strong...

Who Is Accountable for the Medicine in Your Hand?

The Accountability Gap: India’s Drug Regulatory System Your doctor prescribes it. Pharma manufactures it. The regulator approves it. But who ensures...

Who Profits From Trust?

Indian healthcare does not suffer from a shortage of marketing. It suffers from a shortage of trustworthy information patients...

The Great Healthcare Dilemma: Who Will Own the Next Indian Hospital?

The next owner of an Indian hospital may not be the doctor whose name is on the board. Institutional capital...

Indian Pharma’s Three Deficits—and Three Potential Dividends

Indian pharma has already done the hard thing once. It mastered chemistry, manufacturing scale, and generics—becoming indispensable to global healthcare....